Deal Library / Pharma BD Deal Intelligence

Daiichi Sankyo Company, Limited — Pharma Deals

The Pharma Closeout tracks 8 deals, $6.1B in disclosed deal value, 4 with a post-close Outcome Score for Daiichi Sankyo Company, Limited.

Median Critic Score: 78  ·  Median Outcome Score: 54

Best outcome: Daiichi Sankyo Company, Limited / Ambit Biosciences (62)  ·  Weakest outcome: Daiichi Sankyo Company, Limited / Ranbaxy Laboratories Limited (14)

All 8 deals

• Daiichi Sankyo Company, Limited / Ambit Biosciences — 2006 · $410M · Largely worked — most objectives met.
• Daiichi Sankyo Company, Limited / Zepharma Inc. — 2006 · $200M · Mixed — partial payoff, real shortfalls.
• Daiichi Sankyo Company, Limited / Plexxikon Inc. — 2011 · $935M · Mixed — partial payoff, real shortfalls.
• Daiichi Sankyo Company, Limited / Ranbaxy Laboratories Limited — 2008 · $4.6B · Did not work — the deal failed to deliver.
• Daiichi Sankyo Company, Limited / Nosis Biosciences, Inc. — 2025
• Daiichi Sankyo Company, Limited / ViGeneron GmbH — 2022
• Daiichi Sankyo Company, Limited / LogicBio Therapeutics Inc. — 2021
• Daiichi Sankyo Company, Limited / ProLynx LLC — 2019

← Deal Library  ·  Interactive search  ·  How we score deals